Stockreport

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments

Xencor, Inc.  (XNCR) 
Last xencor, inc. earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.xencor.com/investor-relations
PDF MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatme [Read more]